Strides Pharma Science

Strides Pharma Science EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Strides Pharma Science (STAR.NS) as of Nov 22, 2026 is 2.10. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 2.60 — a change of -19.39% (lower).

EV/Revenue

2.10

YoY

-19.39%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Strides Pharma Science is 2025 2.10 . EV/Revenue (Enterprise Value to Revenue) of Strides Pharma Science was 2024 2.60 . It decreases by -19.39% lower compared to the previous year.

The Strides Pharma Science EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2018
3.45 INR
Jan 1, 2019
4.74 INR
Jan 1, 2020
3.56 INR
Jan 1, 2021
3.01 INR
Jan 1, 2022
3.50 INR
Jan 1, 2023
2.87 INR
Jan 1, 2024
2.60 INR
Jan 1, 2025
2.10 INR
The Strides Pharma Science EV/Revenue history
YEAREV/RevenueYoY
2.10-19.39%
2.60-9.15%
2.87-18.09%
3.50+16.31%
3.01-15.43%
3.56-25.00%
4.74+37.48%
3.45+3.34%
3.34-3.80%
3.47-48.39%
6.72+15.27%
5.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strides Pharma Science Stock analysis

What does Strides Pharma Science do? Strides Pharma Science Ltd. generates revenue through the development, manufacturing, and distribution of IP-led generics and bio-pharmaceutical products across its Pharmaceutical and Bio-pharmaceutical segments. The company serves global markets including Africa, Australia, Asia (excluding India), North America, Europe, India, and Others, offering niche pharmaceutical products in various dosage forms such as liquids, creams, ointments, soft gels, sachets, tablets, and modified release formats. Its manufacturing units in Bengaluru, Puducherry, Chennai, Singapore, Milan, Florida, and Nairobi produce anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drugs, alongside soft gelatin capsules. The firm's revenue streams are derived from the sale of its IP-led niche pharmaceutical products to healthcare providers, distributors, and global pharmaceutical companies operating in the specified geographical segments. Key product categories include anti-retroviral, anti-malarial, anti-tuberculosis, and hepatitis treatments, which are distributed through its global manufacturing network. The company's focus on specialized drug segments ensures consistent demand from healthcare systems and institutions managing infectious diseases. Strides Pharma Science Ltd. targets healthcare institutions, distributors, and pharmaceutical companies in regions such as North America, Europe, India, and Africa, where infectious disease management requires specialized treatments. Its manufacturing presence in multiple countries supports direct market access and cost efficiency, enabling the delivery of affordable pharmaceutical solutions. The company's product portfolio emphasizes high-demand therapeutic areas, aligning with global health priorities for infectious disease treatment. Strides Pharma Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strides Pharma Science stock

EV/Revenue (Enterprise Value to Revenue) of Strides Pharma Science is 2.10 in 2025.

EV/Revenue (Enterprise Value to Revenue) of Strides Pharma Science changed from 2.60 to 2.10, representing a -19.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Strides Pharma Science since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Strides Pharma Science with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Strides Pharma Science

All Key Metrics — Strides Pharma Science